The PE Ratio as of November 2024 (TTM) for CSL Limited (CSLLY) is 34.12

According to CSL Limited’s latest financial reports and current stock price. The company's current PE Ratio is 34.12. This represents a change of 168.05% compared to the average of 12.73 of the last 4 quarters.

CSL Limited (CSLLY) Historical PE Ratio (quarterly & annually)

How has CSLLY PE Ratio performed in the past?

The mean historical PE Ratio of CSL Limited over the last ten years is 45.15. The current 34.12 PE Ratio has changed 7.46% with respect to the historical average. Over the past ten years (40 quarters), CSLLY's PE Ratio was at its highest in in the June 2021 quarter at 59.04. The PE Ratio was at its lowest in in the March 2024 quarter at 0.

CSL Limited (CSLLY) PE Ratio by Quarter and Year

Discovering the peaks and valleys of CSL Limited PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

CSL Limited (CSLLY) Average PE Ratio

How has CSLLY PE Ratio performed in the past?

The current PE Ratio of CSL Limited (CSLLY) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

CSL Limited (CSLLY) PE Ratio vs. Peers

How is CSLLY’s PE Ratio compared to its peers?

CSL Limited’s PE Ratio is less than Novo Nordisk A/S (37.32), greater than BeiGene, Ltd. (-41.43), greater than Acelyrin, Inc. (-1.93), greater than Caribou Biosciences, Inc. (-1.71), greater than Molecular Partners AG (-3.01), greater than Mineralys Therapeutics, Inc. (-5.57), greater than AN2 Therapeutics, Inc. (-0.50), greater than Pharvaris N.V. (-10.46), greater than PepGen Inc. (-2.47), greater than Ventyx Biosciences, Inc. (-0.89), greater than CSL Limited (23.61), greater than Bionomics Limited (-9.88), greater than Enzon Pharmaceuticals, Inc. (3.74), greater than Cogent Biosciences, Inc. (-5.19), greater than Larimar Therapeutics, Inc. (-7.46), greater than Kura Oncology, Inc. (-8.49), greater than Kiniksa Pharmaceuticals, Ltd. (-169.90), greater than Cerevel Therapeutics Holdings, Inc. (-17.73), greater than Revolution Medicines, Inc. (-17.77), greater than Nuvalent, Inc. (-33.32), greater than RAPT Therapeutics, Inc. (-0.73), greater than Syndax Pharmaceuticals, Inc. (-6.12), greater than EQRx, Inc. (-13.52),

Build a custom stock screener for CSL Limited (CSLLY) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like CSL Limited using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

CSL Limited (CSLLY) and other stocks custom spreadsheet templates

The easiest way to analyze a company like CSL Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.